Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1994 Feb;120(4):204–207. doi: 10.1007/BF01372557

The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets

Helen E Marr 1, Philip T Davey 1, Elizabeth A Boyle 1, Peter R Blower 1,✉
PMCID: PMC12201080  PMID: 8288674

Abstract

The antiemetic activity of granisetron was examined in ferrets aged 10–13 weeks. Emesis was induced by exposure to either whole-body X-irradiation (50 Gy over 10.4 min) or cyclophosphamide (80 mg/kg i.v.) plus doxorubicin (6 mg/kg i.v.). Following exposure to whole-body X-irradiation, the young ferrets vomited with a similar latency to vomit and severity of emesis to that shown by adult animals. Granisetron (0.5 mg/kg i.v.) significantly reduced (P≤0.05) the number of vomits and retches and two out of four animals were completely protected. Following injection of cyclophosphamide and doxorubicin, the young ferrets showed a reduced emetic, response compared to adult animals. Following a dose of granisetron (0.5 mg/kg i.v.), only one out of four ferrets vomited compared to four out of four in the control group. Further experiments showed that cisplatin (12.5 mg/kg i.v.) was unable to induce vomiting in the young ferret (n=2). Granisetron (0.5 mg/kg i.v.) was well tolerated by the young ferret and was able to reduce significantly or completely abolish emesis induced by cytostatic treatment. The data support the use of granisetron in pediatric patients and clinical trials are currently underway in this patient population.

Key words: Emesis, Granisetron, Cytostatic treatment, 5-HT3

Abbreviation

5-HT3 receptor

5-hydroxytryptamine (serotonin) receptor

References

  1. Allen JC, Gralla R, Reilly L, Kellick M, Young C (1985) Metoclopramide: dose-related toxicity and preliminary anti-emetic studies in children receiving cancer chemotherapy. J Clin Oncol 3:1136–1141 [DOI] [PubMed] [Google Scholar]
  2. Altman AJ, Schwartz AD (1978) Malignant diseases of infancy, childhood and adolescence, vol 18. Saunders, Philadelphia, pp 1–15 [PubMed] [Google Scholar]
  3. Andrews PLR, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR (1992) Are all 5-HT3 receptor antagonists the same? Eur J Cancer 28A [Suppl 1]:52–56 [DOI] [PubMed] [Google Scholar]
  4. Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58:644–650 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carmichael J, Cantwell BMJ, Edwards CM, Rapeport WG, Harris AL (1988) The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin. Br Med J 297:110–111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rep 66:187–189 [PubMed] [Google Scholar]
  7. Frick SB, Delpo EG, Keith JA, Davis MS (1988) Chemotherapy-associated nausea and vomiting in paediatric oncology patients. Cancer Nurs 11:118–124 [PubMed] [Google Scholar]
  8. Gralla RJ, Tyson LB, Kris MG, Clark RA (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 781:289–301 [DOI] [PubMed] [Google Scholar]
  9. Hoff J van, Hockenberry-Eaton MN, Patterson K, Hutter JJ (1991) A survey of anti-emetic use in children with cancer. Am J Dis Child 145:773–778 [PubMed] [Google Scholar]
  10. Jacobson SJ, Shore RW, Nishimura L, Mee D, Chai H, Spielberg SP (1991) Efficacy and safety of granisetron in paediatric cancer patients who had failed standard anti-emetic therapy during anti-cancer chemotherapy. Eur J Cancer 27 [Suppl 1]:1578 [Google Scholar]
  11. Leclerc JM, Lafrenière D, Alarie D, Demanche C, Beauchamp D, Larocque D (1991) Efficacy of a specific serotonin receptor antagonist (granisetron, BRL 43694A) to inhibit vomiting in children receiving repeated cycles of high-dose Ara-C. Presented at the Forth Annual Meeting. The American Society of Paediatric Haematology/Oncology, Chicago 1991
  12. Marr HE, Davey PT, Blower PR (1990) Further studies of the anti-emetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Poster presented at ICSCO, Brussels, Belgium, August 1990
  13. Miner WD, Sanger GJ (1986) Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497–499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sanger GJ, Nelson DR (1989) Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 159:113–124 [DOI] [PubMed] [Google Scholar]
  15. Smith SD, Rosen D, Trueworthy RC et al. (1979) A reliable method for evaluating drug compliance in children with cancer. Cancer 43:169–173 [DOI] [PubMed] [Google Scholar]
  16. Soukop M on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 [Suppl 1]:S15-S19 [PubMed] [Google Scholar]
  17. Sumer T, Abu-Melha A, Maqbool G, Al-Mulhim I (1988) Dexamethasone as an anti-emetic in children receiving cis-platinum. Am J Pediatr Hematol Oncol 10:126–128 [Google Scholar]
  18. Wijngaarden I van, Tulp MTM, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol Mol Biol 188:301–312 [DOI] [PubMed] [Google Scholar]
  19. Zeltzer L, LeBaron S, Zeltzer PM (1984) The effectiveness of behavioral intervention for reduction of nausea and vomiting in children and adolescents receiving chemotherapy. J Clin Oncol 2:683–690 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES